Ces radiol. 2011, 65(3):190-195

18F-FDG-PET/CT in renal-cell carcinomaOriginal article

Jiří Ferda1, Eva Ferdova1, Milan Hora2, Ondřej Hes3
1 Klinika zobrazovacích metod LF UK a FN, Plzeň
2 Urologická klinika LF UK a FN, Plzeň
3 Šiklův ústav patologické anatomie LF UK a FN, Plzeň

Aim: To assess the impact of 18F-FDG-PET/CT on the treatment decision in renal cell carcinoma.

Method: The analysis of the sample of 40 patients was made; it consists of 28 males, 12 females, mean age 67.8 years, ranging 53-86 years. All patients underwent 18F-FDG-PET/CT including two-phase CT-angiography of the kidneys, locally advanced or generalized renal cell carcinoma was suspected in all patients. The level of the 18F-FDG accumulation within the tumor was compared with the histological grading and the development of the disease was surveyed twelve months after 18F-FDG-PET/CT.

Results: Overall mortality reached 45%, the highest 18F-FDG accumulation showed tumor of the grade 4 (mean SUVmax 10.4, ranging 5-22), the highest mortality was present in tumors exceeded the SUVmax value of 10 (mortality 63.6%). New information was brought by 18F-FDG-PET/CT in comparison to CT in 87.5%.

Conclusion: 18F-FDG-PET/CT is useful tool to make decision about the way of treatment especially when the generalization is confirmed or excluded; the method is bearing the potential to set the prognosis according the reached value of 18F-FDG accumulation measured in SUVmax.

Keywords: renal cell carcinoma, 18F-FDG-PET, CT, hybrid imaging

Accepted: July 15, 2011; Published: September 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ferda J, Ferdova E, Hora M, Hes O. 18F-FDG-PET/CT in renal-cell carcinoma. Ces radiol. 2011;65(3):190-195.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma N Engl J Med 1996; 335: 865-875. Go to original source... Go to PubMed...
    2. Mueller-Lisse UG, Mueller-Lisse UL, Meindl T, et al. Staging of renal cell carcinoma. Eur Radiol 2007; 17(9): 2268-2277. Go to original source... Go to PubMed...
    3. Ferda J, Hora M, Hes O, Ferdová E, Kreuzberg B. Assessment of the kidney tumor vascular supply by two-phase MDCT-angiography. Eur J Radiol 2007; 62(2): 295-301. Go to original source... Go to PubMed...
    4. Aide N, Cappele O, Bottet P, et al. Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging 2003; 30(9): 1236-1245. Go to original source... Go to PubMed...
    5. Lawrentschuk N, Davis ID, Bolton DM, Scott AM. Functional imaging of renal cell carcinoma. Nat Rev Urol 2010; 7(5): 258-266. Go to original source... Go to PubMed...
    6. Ide M, Suzuki Y, Kameyama G, et al. The detection of renal cell carcinoma with adrenal and para-aortic lymph node metastases by FDG-PET. Eur J Nucl Med Mol Imaging 2005; 32(10): 1246. Go to original source... Go to PubMed...
    7. Nakatani K, Nakamoto Y, Saga T, Higashi T, Togashi K. The potential clinical value of FDG-PET for recurrent renal cell carcinoma. Eur J Radiol 2011; 79(1): 29-35. Go to original source... Go to PubMed...
    8. Namura K, Minamimoto R, Yao M, et al. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer 2010; 10: 667. Go to original source... Go to PubMed...
    9. Lyrdal D, Boijsen M, Suurküla M, Lundstam S, Stierner U. Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. Nucl Med Commun 2009; 30(7): 519-524. Go to original source... Go to PubMed...
    10. Hugonnet F, Fournier L, Medioni J, Smadja C, Hindié E, Huchet V, Itti E, Cuenod CA, Chatellier G, Oudard S, Faraggi M; Hypoxia in Renal Cancer Multicenter Group. Metastatic renal cell carcinoma: relationship between initial metastasi hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study. J Nucl Med 2011; 52(7): 1048-1055. Go to original source... Go to PubMed...
    11. Kotzerke J, Linné C, Meinhardt M, et al. [1-(11)C]acetate uptake is not increased in renal cell carcinoma. Eur J Nucl Med Mol Imaging 2007; 34(6): 884-888. Go to original source... Go to PubMed...
    12. Oyama N, Okazawa H, Kusukawa N, et al. 11C-Acetate PET imaging for renal cell carcinoma. Eur J Nucl Med Mol Imaging 2009; 36(3): 422-427. Go to original source... Go to PubMed...
    13. Middendorp M, Maute L, Sauter B, Vogl TJ, Grünwald F. Initial experience with 18F-fluoroethylcholine PET/CT in staging and monitoring therapy response of advanced renal cell carcinoma. Ann Nucl Med 2010; 24(6): 441-446. Go to original source... Go to PubMed...
    14. Lawrentschuk N, Poon AM, Scott AM. Fluorine-18 fluorothymidine: a new positron emission radioisotope for renal tumors. Clin Nucl Med 2006; 31(12): 788-789. Go to original source... Go to PubMed...
    15. Lawrentschuk N, Poon AM, Foo SS, et al. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int 2005; 96(4): 540-546. Go to original source... Go to PubMed...
    16. Lawrentschuk N, Gani J, Riordan R, Esler S, Bolton DM. Multidetector computed tomography vs magnetic resonance imaging for defining the upper limit of tumour thrombus in renal cell carcinoma: a study and review. BJU Int 2005; 96(3): 291-295. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content